Beth Rosenshein is an electrical/bio-medical engineer and is very familiar with medical research. She holds two United States patents, one for a unique design of vaginal speculum, and one for a clever urinary collection device specifically designed for women. Beth discovered and documented an important drug interaction between esomeprazole (Nexiumª) and testosterone. Her findings were published in a case study in The American Journal of the Medical Sciences in May 2004. She petitioned the FDA in August 2003 to change the labeling on hormone products. The petition was granted in September 2004. Beth is also a wife and mother and lives in Seattle, Washington.